Neutrophilia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 5,593 adverse event reports that record the MedDRA preferred term Neutrophilia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 318 reports in the 12 months to June 2026 and 602 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,205 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 318 (under 0.1%) record this term. Reports for male patients were 50.9% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 111 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Neutrophilia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		21
Actonel	Bisphosphonate	20
Advair Hfa	Corticosteroid	11
Aflibercept	Vascular endothelial growth factor inhibitor	18
Albuterol	beta2-Adrenergic agonist	40
Albuterol sulfate	beta2-Adrenergic agonist	24
Allopurinol	Xanthine oxidase inhibitor	20
Altace		63
Amlodipine	Calcium channel blocker	33
Amoxicillin	Penicillin-class antibacterial	32
Aripiprazole	Atypical antipsychotic	36
Atezolizumab	Programmed death Receptor-1 blocking antibody	13
Atorvastatin		26
Avastin	Vascular endothelial growth factor inhibitor	12
Azathioprine	Purine antimetabolite	13
Azithromycin	Macrolide antimicrobial	18
Azithromycin Anhydrous		10
Bevacizumab	Vascular endothelial growth factor inhibitor	32
Biperiden		14
Budesonide	Corticosteroid	74
Budesonide and formoterol fumarate	Corticosteroid	13
Budesonide Formoterol Fumarate		27
Capecitabine	Nucleoside metabolic inhibitor	33
Carbamazepine	Mood stabilizer	11
Carboplatin	Platinum-based drug	61
Cefepime	Cephalosporin antibacterial	18
Ceftriaxone	Cephalosporin antibacterial	27
Ceftriaxone sodium	Cephalosporin antibacterial	13
Ciprofloxacin	Fluoroquinolone antibacterial	39
Cisplatin	Platinum-based drug	24
Clindamycin	Lincosamide antibacterial	13
Clonazepam	Benzodiazepine	22
Clopidogrel	P2Y12 platelet inhibitor	44
Clopidogrel bisulfate	P2Y12 platelet inhibitor	52
Clozapine	Atypical antipsychotic	2,130
Clozapine Accord		268
Clozaril	Atypical antipsychotic	932
Colchicine	Alkaloid	28
Cyclophosphamide	Alkylating drug	38
Cyclosporine	Calcineurin inhibitor immunosuppressant	20
Dexamethasone	Corticosteroid	52
Diazepam	Benzodiazepine	43
Docetaxel	Microtubule inhibitor	22
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	20
Etoposide	Topoisomerase inhibitor	16
Filgrastim	Leukocyte growth factor	18
Fluorouracil	Nucleoside metabolic inhibitor	31
Fluoxetine	Serotonin reuptake inhibitor	17
Fluticasone Furoate Vilanterol Trifenatate		19
Folinic Acid		12
Formoterol		16
Formoterol fumarate	beta2-Adrenergic agonist	16
Gabapentin	Anti-epileptic agent	16
Haloperidol	Typical antipsychotic	11
Humira		24
Hydrochlorothiazide	Thiazide diuretic	87
Hydroxychloroquine	Antimalarial	11
Ibuprofen	Nonsteroidal anti-inflammatory drug	62
Imatinib	Kinase inhibitor	10
Indapamide	Thiazide-like diuretic	14
Irinotecan		16
Janumet	Biguanide	11
Lamotrigine	Anti-epileptic agent	37
Lansoprazole	Proton pump inhibitor	20
Lantus	Insulin analog	11
Levetiracetam		14
Lithium	Mood stabilizer	17
Lithium carbonate	Mood stabilizer	12
Metformin	Biguanide	100
Metformin hydrochloride	Biguanide	17
Methotrexate	Folate analog metabolic inhibitor	34
Methylprednisolone	Corticosteroid	27
Metronidazole	Nitroimidazole antimicrobial	17
Mirtazapine		15
Mycophenolate mofetil	Antimetabolite immunosuppressant	30
Nitrofurantoin	Nitrofuran antibacterial	11
Nivolumab	Programmed death Receptor-1 blocking antibody	10
Olanzapine	Atypical antipsychotic	36
Omeprazole	Proton pump inhibitor	32
Oxaliplatin	Platinum-based drug	37
Oxazepam	Benzodiazepine	12
Paclitaxel	Microtubule inhibitor	23
Pantoprazole	Proton pump inhibitor	34
Paracetamol		29
Pemetrexed	Folate analog metabolic inhibitor	12
Prednisolone	Corticosteroid	71
Prednisone	Corticosteroid	162
Pregabalin		18
Pulmicort Turbuhaler		29
Quetiapine	Atypical antipsychotic	18
Rabeprazole	Proton pump inhibitor	36
Rabeprazole sodium	Proton pump inhibitor	53
Ramipril	Angiotensin converting enzyme inhibitor	29
Risedronate sodium	Bisphosphonate	73
Risperidone	Atypical antipsychotic	36
Rituximab	CD20-directed cytolytic antibody	19
Salbutamol		11
Salbutamol sulfate		22
Scopolamine hydrobromide		18
Sertraline	Serotonin reuptake inhibitor	19
Sitagliptin	Dipeptidyl peptidase 4 inhibitor	19
Symbicort	Corticosteroid	37
Tacrolimus	Calcineurin inhibitor immunosuppressant	10
Terbinafine	Allylamine antifungal	18
Tiotropium bromide	Anticholinergic	13
Trastuzumab	HER2/neu receptor antagonist	11
Valproate sodium	Anti-epileptic agent	10
Valproic acid	Anti-epileptic agent	13
Vancomycin	Glycopeptide antibacterial	30
Ventolin Hfa	beta2-Adrenergic agonist	13
Zopiclone		12

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 37 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Neutrophilia name, in order of name
Class	Reports with this term
Alkaloid	28
Alkylating drug	50
Angiotensin converting enzyme inhibitor	38
Anti-epileptic agent	78
Anticholinergic	27
Antimetabolite immunosuppressant	36
Atypical antipsychotic	3,206
Benzodiazepine	90
beta2-Adrenergic agonist	93
Biguanide	128
Bisphosphonate	93
Calcineurin inhibitor immunosuppressant	34
Calcium channel blocker	33
CD20-directed cytolytic antibody	27
Cephalosporin antibacterial	77
Corticosteroid	476
Dipeptidyl peptidase 4 inhibitor	25
Fluoroquinolone antibacterial	43
Folate analog metabolic inhibitor	54
Glycopeptide antibacterial	30
HMG-CoA reductase inhibitor	25
Kinase inhibitor	76
Leukocyte growth factor	31
Microtubule inhibitor	48
Mood stabilizer	42
Nonsteroidal anti-inflammatory drug	79
Nucleoside metabolic inhibitor	79
P2Y12 platelet inhibitor	96
Penicillin-class antibacterial	46
Platinum-based drug	122
Programmed death Receptor-1 blocking antibody	42
Proton pump inhibitor	180
Serotonin and norepinephrine reuptake inhibitor	30
Serotonin reuptake inhibitor	48
Thiazide diuretic	87
Tumor necrosis factor blocker	25
Vascular endothelial growth factor inhibitor	62

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Neutrophilia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Neutrophilia
Age	Reports	Share
Under 2	30	0.5%
2 to 11	79	1.4%
12 to 17	71	1.3%
18 to 44	1,271	22.7%
45 to 64	1,855	33.2%
65 to 74	1,000	17.9%
75 and over	442	7.9%
Age not given	845	15.1%

Sex of the patient in the reports that record Neutrophilia
Sex	Reports	Share
Female	2,407	43%
Male	2,847	50.9%
Unknown or not given	339	6.1%

Age and sex are as the report gives them. 47.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Neutrophilia: adverse event reports that record this term. https://reportedreactions.com/reaction/neutrophilia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Neutrophilia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page